An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Someone who’s been taking Effexor XR (venlafaxine, an antidepressant) for about a year started a GLP‑1 medication (a semaglutide-type drug like Wegovy/Ozempic) at a low dose and noticed appetite dropped and nausea almost right away. They’re asking if others who were already on venlafaxine experienced the same when they began a GLP‑1. The post sounds like a personal report, not a formal study. Semaglutide is the active drug in brand names like Ozempic and Wegovy. It’s a man‑made version of a natural hormone your gut makes after you eat. That hormone tells your brain you’re full and slows how fast food leaves your stomach. In plain terms, semaglutide helps reduce hunger and can make people feel full sooner, which is why it’s used for weight loss and for blood sugar control in diabetes. The snippet is just an anecdote — one person’s experience — not a clinical trial. It doesn’t provide systematic data, control groups, or numbers. From what they wrote: they started on a low dose of the GLP‑1 and quickly had reduced appetite and nausea. That’s consistent with what many people report when starting semaglutide: appetite suppression and gastrointestinal side effects are common, especially early on. But this single report doesn’t tell us whether venlafaxine changed the experience, made side effects worse, or had no effect at all. Why this matters is practical. Lots of people take antidepressants like venlafaxine and are also considering or prescribed GLP‑1 drugs for weight loss or diabetes. If starting a GLP‑1 quickly reduces appetite or causes nausea, that could affect mood, energy, and how well an antidepressant seems to be working. People managing depression need to know whether new drugs might change their symptoms or cause new side effects that could be mistaken for relapse or medication problems. Important caveats: this one message is not evidence of a drug interaction. Semaglutides commonly cause nausea, vomiting, and decreased appetite even without other medications. Venlafaxine has its own side effects and can affect appetite and nausea too. There are known interactions and precautions with many drugs, but published data specifically about venlafaxine plus semaglutide are limited. If someone has severe nausea, new mood changes, or other worrying symptoms after starting a GLP‑1 while on an antidepressant, they should contact their prescriber. Only a clinician can advise whether to adjust doses, change medications, or investigate other causes. Bottom line: the post describes a common early reaction to semaglutide (less appetite and nausea), but it’s just one person’s report and doesn’t prove an interaction with venlafaxine — talk to your doctor if you notice new or worsening symptoms.
Source: r/Semaglutide